XLS

Research XLS on Bullrun: market cap EUR 86.84M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 86.84M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CHF 275.31K-CHF 21.55M-CHF 1.28M3.4%-3.76CHF 404.41KCHF 60.00MCHF 286.53M
FY2024CHF 834.88KCHF 34.28M-CHF 433.60K65.8%4.69CHF 99.03KCHF 59.25MCHF 305.26M
FY2023CHF 988.44KCHF 14.88MCHF 130.70K45.4%2.08CHF 218.71KCHF 56.52MCHF 268.17M
FY2022CHF 1.03MCHF 14.31M-CHF 4.69M18.1%2CHF 221.04KCHF 60.35MCHF 235.23M
FY2021CHF 806.07KCHF 53.42M-CHF 5.54M44.6%8.66CHF 1.96MCHF 62.97MCHF 211.23M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-28EUR 86.84Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About XLS

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indication areas;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is XLS's market cap?

XLS's market capitalization is EUR 86.84M.

What does XLS do?

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services.